Interestingly, we found decreased N-myc expression with increasing doses of pralatrexate in both BE(2)-C and CHP-212 cells (Figure 3B), demonstrating persistent defects in proliferative potential induced by pralatrexate in neuroblastoma. The gene discussed is MYCN; the disease is neuroblastoma.